IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.93
+7.72%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 15.37x
- P/S forward
- 30.94x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -9.04x
- Price / sales
- 57.09x
- Price / cash flow
- -33.66x
Enterprise value
- Enterprise value
- $9.9B
- EV / sales
- 59.84x
- EV / EBITDA
- -11.11x
- EV / EBIT
- -39.40x
- Market cap
- $9.5B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026